Potential clinical impact of multiparametric quantitative MR spectroscopy in neurological disorders: A review and analysis

Unlike conventional MR spectroscopy (MRS), which only measures metabolite concentrations, multiparametric MRS also quantifies their longitudinal (T1) and transverse (T2) relaxation times, as well as the radiofrequency transmitter inhomogeneity (B1+). To test whether knowledge of these additional parameters can improve the clinical utility of brain MRS, we compare the conventional and multiparametric approaches in terms of expected classification accuracy in differentiating controls from patients with neurological disorders.

[1]  Kubilay Aydin,et al.  Altered Metabolic Integrity of Corpus Callosum Among Individuals at Ultra High Risk of Schizophrenia and First-Episode Patients , 2008, Biological Psychiatry.

[2]  Peter Kapeller,et al.  Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study , 2001, Journal of Neurology.

[3]  Geraldine Dawson,et al.  Gray and white matter brain chemistry in young children with autism. , 2006, Archives of general psychiatry.

[4]  Zografos Caramanos,et al.  Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b , 2001, Journal of Neurology.

[5]  L DelaBarre,et al.  The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. , 2001, Journal of magnetic resonance.

[6]  C. Laule,et al.  Proton MRS of large multiple sclerosis lesions reveals subtle changes in metabolite T1 and area , 2010, NMR in biomedicine.

[7]  Khader M Hasan,et al.  Multi‐modal quantitative MRI investigation of brain tissue neurodegeneration in multiple sclerosis , 2012, Journal of magnetic resonance imaging : JMRI.

[8]  I D Wilkinson,et al.  Cerebral magnetic resonance relaxometry in HIV infection. , 1996, Magnetic resonance imaging.

[9]  Jim Mintz,et al.  In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI , 1994, Biological Psychiatry.

[10]  G. Bartzokis,et al.  Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical “disconnection” in aging and Alzheimer’s disease , 2004, Neurobiology of Aging.

[11]  U. Ziemann,et al.  Combined 1H and 31P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis , 2011, NMR in biomedicine.

[12]  R. Harper,et al.  Age‐related regional brain T2‐relaxation changes in healthy adults , 2012, Journal of magnetic resonance imaging : JMRI.

[13]  David H. Miller,et al.  The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis , 2002, Journal of Neurology.

[14]  Kevin M Bradley,et al.  Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. , 2002, Brain : a journal of neurology.

[15]  A. Mackay,et al.  In vivo measurement of T2 distributions and water contents in normal human brain , 1997, Magnetic resonance in medicine.

[16]  H. Soininen,et al.  Severity of hippocampal atrophy correlates with the prolongation of MRI T sub 2 relaxation time in temporal lobe epilepsy but not in Alzheimer's disease , 1996, Neurology.

[17]  K. Jhaveri,et al.  Feasibility of in-vivo semi-LASER renal magnetic resonance spectroscopy (MRS): Pilot study in healthy volunteers. , 2017, Magnetic resonance imaging.

[18]  Michael Wagner,et al.  N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. , 2013, Schizophrenia bulletin.

[19]  Linda Chang,et al.  Relationships among Brain Metabolites, Cognitive Function, and Viral Loads in Antiretroviral-Naı̈ve HIV Patients , 2002, NeuroImage.

[20]  Oded Gonen,et al.  Age dependence of regional proton metabolites T2 relaxation times in the human brain at 3 T , 2008, Magnetic resonance in medicine.

[21]  I. Akiguchi,et al.  Absolute Quantification in Proton Magnetic Resonance Spectroscopy Is Useful to Differentiate Amnesic Mild Cognitive Impairment from Alzheimer’s Disease and Healthy Aging , 2010, Dementia and Geriatric Cognitive Disorders.

[22]  A. Srivastava,et al.  Case control study: magnetic resonance spectroscopy of brain in HIV infected patients , 2016, BMC Neurology.

[23]  A. Thompson,et al.  Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis , 2002, Multiple sclerosis.

[24]  Jens Frahm,et al.  Localized proton MRS of the human hippocampus: Metabolite concentrations and relaxation times , 1999, Magnetic resonance in medicine.

[25]  A. Townsend Peterson,et al.  Rethinking receiver operating characteristic analysis applications in ecological niche modeling , 2008 .

[26]  J. Lauriello,et al.  1H-MRS at 4 Tesla in minimally treated early schizophrenia , 2010, Molecular Psychiatry.

[27]  R S Balaban,et al.  MR relaxation times in human brain: measurement at 4 T. , 1996, Radiology.

[28]  P. Renshaw,et al.  T2 relaxation time abnormalities in bipolar disorder and schizophrenia , 2010, Magnetic resonance in medicine.

[29]  H. Soininen,et al.  MR T2 relaxometry in Alzheimer's disease and age-associated memory impairment , 1996, Neurobiology of Aging.

[30]  Klaus Scheffler,et al.  Signal‐to‐noise ratio and MR tissue parameters in human brain imaging at 3, 7, and 9.4 tesla using current receive coil arrays , 2016, Magnetic resonance in medicine.

[31]  Declan G. M. Murphy,et al.  Hippocampal Proton MR Spectroscopy in Early Alzheimer’s Disease and Mild Cognitive Impairment , 2011, Brain Topography.

[32]  S. Topp,et al.  Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy , 1997, Neurology.

[33]  Arend Heerschap,et al.  Towards 1H-MRSI of the human brain at 7T with slice-selective adiabatic refocusing pulses , 2008, Magnetic Resonance Materials in Physics, Biology and Medicine.

[34]  P Kapeller,et al.  Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[35]  J. Frahm,et al.  Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites , 1989, Magnetic resonance in medicine.

[36]  G. Fein,et al.  Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. , 1998, Radiology.

[37]  Rohit Bakshi,et al.  3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis , 2009, NeuroImage.

[38]  Stéphane Lehéricy,et al.  Single‐voxel 1H spectroscopy in the human hippocampus at 3 T using the LASER sequence: characterization of neurochemical profile and reproducibility , 2015, NMR in biomedicine.

[39]  D R Rutgers,et al.  Relaxation times of choline, creatine and N‐acetyl aspartate in human cerebral white matter at 1.5 T , 2002, NMR in biomedicine.

[40]  F Träber,et al.  Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. , 1998, Archives of neurology.

[41]  E Moser,et al.  Proton T 1 and T 2 relaxation times of human brain metabolites at 3 Tesla , 2001, NMR in biomedicine.

[42]  Craig Malloy,et al.  A comparative study of short‐ and long‐TE 1H MRS at 3 T for in vivo detection of 2‐hydroxyglutarate in brain tumors , 2013, NMR in biomedicine.

[43]  Andreas Meyer-Lindenberg,et al.  MR spectroscopic evaluation of N-acetylaspartate's T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia , 2009, NeuroImage.

[44]  A. Mackay,et al.  Proton T1 relaxation times of cerebral metabolites differ within and between regions of normal human brain , 2003, NMR in biomedicine.

[45]  Gadi Goelman,et al.  Optimizing the efficiency of high‐field multivoxel spectroscopic imaging by multiplexing in space and time , 2006, Magnetic resonance in medicine.

[46]  Bo Zhu,et al.  MR fingerprinting Deep RecOnstruction NEtwork (DRONE) , 2017, Magnetic resonance in medicine.

[47]  F. Fazekas,et al.  Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H—magnetic resonance spectroscopy , 2005, Journal of Neurology.

[48]  S. Dunham,et al.  A phase rotation scheme for achieving very short echo times with localized stimulated echo spectroscopy. , 2005, Magnetic resonance imaging.

[49]  Vinzenz Fleischer,et al.  Multi-parametric quantitative MRI of normal appearing white matter in multiple sclerosis, and the effect of disease activity on T2 , 2016, Brain Imaging and Behavior.

[50]  T. Ernst,et al.  Abnormal cerebral metabolite concentrations in patients with probable alzheimer disease , 1994, Magnetic resonance in medicine.

[51]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[52]  S. Nelson,et al.  Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. , 2014, JAMA neurology.

[53]  A J Thompson,et al.  Normal-appearing grey and white matter T1 abnormality in early relapsing–remitting multiple sclerosis: a longitudinal study , 2007, Multiple sclerosis.

[54]  R. Real,et al.  AUC: a misleading measure of the performance of predictive distribution models , 2008 .

[55]  Edward J. Auerbach,et al.  Single-voxel 1 H spectroscopy in the human hippocampus at 3 T using the LASER sequence , 2015 .

[56]  H. Schild,et al.  Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. , 2001, Archives of neurology.

[57]  C. Elster,et al.  Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-β therapy on absolute metabolite concentrations , 2002, Magnetic Resonance Materials in Physics, Biology and Medicine.

[58]  P. Matthews.  Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. , 2001, Journal of neurology.

[59]  Shigehiro Morikawa,et al.  The Profile of Hippocampal Metabolites Differs between Alzheimer's Disease and Subcortical Ischemic Vascular Dementia, as Measured by Proton Magnetic Resonance Spectroscopy , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[60]  J. Swets.  Indices of discrimination or diagnostic accuracy: their ROCs and implied models. , 1986, Psychological bulletin.

[61]  Huali Wang,et al.  Prolongation of T2 relaxation times of hippocampus and amygdala in Alzheimer's disease , 2004, Neuroscience Letters.

[62]  F. Barkhof,et al.  Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. , 2006, Radiology.

[63]  F Träber,et al.  A multicenter 1H-MRS study of the medial temporal lobe in AD and MCI , 2009, Neurology.

[64]  Jürgen Gallinat,et al.  Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla , 2004, NeuroImage.

[65]  Jürgen Gieseke,et al.  1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation , 2004, Journal of magnetic resonance imaging : JMRI.

[66]  B D Ross,et al.  Absolute Quantitation of Water and Metabolites in the Human Brain. II. Metabolite Concentrations , 1993 .

[67]  N. Voets,et al.  Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER , 2016, Tomography.

[68]  Linda Chang,et al.  Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction , 2007, Biological Psychiatry.

[69]  Robert Bartha,et al.  Effect of signal‐to‐noise ratio and spectral linewidth on metabolite quantification at 4 T , 2007, NMR in biomedicine.

[70]  R. Kauppinen,et al.  Quantitative Metabolite Patterns of Human Brain Tumors: Detection by 1H NMR Spectroscopy In Vivo and In Vitro , 1994, Journal of computer assisted tomography.

[71]  C H Polman,et al.  MR spectroscopic evidence for glial increase but not for neuro‐axonal damage in MS normal‐appearing white matter , 2005, Magnetic resonance in medicine.

[72]  P M Pattany,et al.  MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. , 2000, AJNR. American journal of neuroradiology.

[73]  Craig K. Jones,et al.  Normal‐appearing white matter in multiple sclerosis has heterogeneous, diffusely prolonged T2 , 2002, Magnetic resonance in medicine.

[74]  O. Khan,et al.  Long‐Term Study of Brain 1H‐MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long‐Term 1H‐MRS Monitoring in Multiple Sclerosis , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[75]  P. Jezzard,et al.  Thalamic neurodegeneration in relapsing-remitting multiple sclerosis , 2003, Neurology.

[76]  R Stollberger,et al.  A comparison of magnetization transfer ratio, magnetization transfer rate, and the native relaxation time of water protons related to relapsing-remitting multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[77]  Akira Matsumura,et al.  Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. , 2002, Magnetic resonance imaging.

[78]  S. Holland,et al.  NMR relaxation times in the human brain at 3.0 tesla , 1999, Journal of magnetic resonance imaging : JMRI.

[79]  N. Graham,et al.  Areas beneath the relative operating characteristics (ROC) and relative operating levels (ROL) curves: Statistical significance and interpretation , 2002 .

[80]  Dushyant Kumar,et al.  The Correlation of Hippocampal T2-Mapping with Neuropsychology Test in Patients with Alzheimer’s Disease , 2013, PloS one.

[81]  Lili Tian,et al.  Combining large number of weak biomarkers based on AUC , 2015, Statistics in medicine.

[82]  M. Oudkerk,et al.  1H chemical shift imaging characterization of human brain tumor and edema , 2002, European Radiology.

[83]  Peter Boesiger,et al.  SPECIAL semi‐LASER with lipid artifact compensation for 1H MRS at 7 T , 2013, Magnetic resonance in medicine.

[84]  C. Jack,et al.  Hippocampal transverse relaxation times in patients with Alzheimer disease. , 1997, Radiology.

[85]  N. Schuff,et al.  Effects of Alzheimer Disease on Fronto-parietal Brain N-acetyl Aspartate and Myo-Inositol Using Magnetic Resonance Spectroscopic Imaging , 2006, Alzheimer disease and associated disorders.

[86]  M. Filippi,et al.  Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[87]  Jullie W Pan,et al.  Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T , 1994, Magnetic resonance in medicine.

[88]  Guan Wang,et al.  Minimum acquisition methods for simultaneously imaging T(1), T(2), and proton density with B(1) correction and no spin-echoes. , 2014, Journal of magnetic resonance.

[89]  Huali Wang,et al.  Prolongation of T(2) relaxation times of hippocampus and amygdala in Alzheimer's disease. , 2004, Neuroscience letters.

[90]  Jürgen Gallinat,et al.  Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: A combined MRI and 1H-MRS study , 2010, NeuroImage.

[91]  C. Hanstock,et al.  Reduction in metabolite transverse relaxation times in amyotrophic lateral sclerosis , 2002, Journal of the Neurological Sciences.

[92]  A. Haley,et al.  Shortening of hippocampal spin-spin relaxation time in probable Alzheimer's disease: a 1H magnetic resonance spectroscopy study , 2004, Neuroscience Letters.

[93]  A Horsman,et al.  Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumours , 1995, NMR in biomedicine.

[94]  Assaf Tal,et al.  Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS , 2013, Neurology.

[95]  J. Duerk,et al.  Magnetic Resonance Fingerprinting , 2013, Nature.

[96]  K O Lim,et al.  In vivo spectroscopic quantification of the N‐acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging , 1999, Magnetic resonance in medicine.

[97]  Karl Landheer,et al.  A rapid inversion technique for the measurement of longitudinal relaxation times of brain metabolites: application to lactate in high‐grade gliomas at 3 T , 2016, NMR in biomedicine.

[98]  K. Choe,et al.  Proton T2 measurement and quantification of lactate in brain tumors by MRS at 3 Tesla in vivo , 2015, Magnetic resonance in medicine.

[99]  Vinzenz Fleischer,et al.  Assessment of cortical damage in early multiple sclerosis with quantitative T2 relaxometry , 2016, NMR in biomedicine.

[100]  N. Gourtsoyiannis,et al.  T2 relaxation time analysis in patients with multiple sclerosis: correlation with magnetization transfer ratio , 2004, European Radiology.

[101]  Michael Erb,et al.  Comparison of longitudinal metabolite relaxation times in different regions of the human brain at 1.5 and 3 Tesla , 2003, Magnetic resonance in medicine.

[102]  P. Matthews,et al.  White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis , 2002, Journal of Neurology.

[103]  O. Volovyk,et al.  Application of phase rotation to STRESS localization scheme at 3 T , 2018, Magnetic resonance in medicine.

[104]  Peter Jezzard,et al.  Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. , 2016, Cancer research.

[105]  J S Duncan,et al.  Technique for measuring hippocampal T2 relaxation time. , 1996, AJNR. American journal of neuroradiology.

[106]  A. Thompson,et al.  Metabolite changes in early relapsing–remitting multiple sclerosis , 2006, Journal of Neurology.

[107]  I. Wilkinson,et al.  Proton spectroscopy in HIV infection: relaxation times of cerebral metabolites. , 1994, Magnetic resonance imaging.

[108]  Assaf Tal,et al.  The application of magnetic resonance fingerprinting to single voxel proton spectroscopy , 2018, NMR in biomedicine.

[109]  G. Fein,et al.  Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.

[110]  D. Sodickson,et al.  New rapid, accurate T2 quantification detects pathology in normal-appearing brain regions of relapsing-remitting MS patients , 2017, NeuroImage: Clinical.

[111]  P. Pattynama,et al.  Receiver operating characteristic (ROC) analysis: basic principles and applications in radiology. , 1998, European journal of radiology.

[112]  Vinzenz Fleischer,et al.  Multimodal quantitative MRI assessment of cortical damage in relapsing‐remitting multiple sclerosis , 2016, Journal of magnetic resonance imaging : JMRI.

[113]  G. Dawson,et al.  Regional brain chemical alterations in young children with autism spectrum disorder , 2003, Neurology.

[114]  D. Arnold,et al.  Neuroprotection with glatiramer acetate: evidence from the PreCISe trial , 2013, Journal of Neurology.

[115]  Lili Tian,et al.  Linear combination methods to improve diagnostic/prognostic accuracy on future observations , 2016, Statistical methods in medical research.

[116]  E. Rosenberg,et al.  Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection , 2009, Neurology.

[117]  O. Henriksen,et al.  Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. , 1995, Magnetic resonance imaging.

[118]  J. Babb,et al.  Brain metabolite proton T2 mapping at 3.0 T in relapsing-remitting multiple sclerosis. , 2010, Radiology.

[119]  O. Gonen,et al.  Spectroscopic localization by simultaneous acquisition of the double‐spin and stimulated echoes , 2015, Magnetic resonance in medicine.

[120]  D. Auer,et al.  Deep gray matter and fatigue in MS , 2006, Journal of Neurology.

[121]  Larry L. Butcher,et al.  Prolongation of magnetic resonance T 2 time in hippocampus of human patients marks the presence and severity of Alzheimer's disease , 1992, Neuroscience Letters.

[122]  Rolf Gruetter,et al.  Proton T1 relaxation times of metabolites in human occipital white and gray matter at 7 T , 2013, Magnetic resonance in medicine.

[123]  Daniel K Sodickson,et al.  Rapid and accurate T2 mapping from multi–spin‐echo data using Bloch‐simulation‐based reconstruction , 2015, Magnetic resonance in medicine.

[124]  J R MacFall,et al.  T2 estimates in healthy and diseased brain tissue: a comparison using various MR pulse sequences. , 1986, Radiology.

[125]  I. Akiguchi,et al.  Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer’s disease , 2012, Neurobiology of Learning and Memory.

[126]  Daniel Pelletier,et al.  Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. , 2005, Brain : a journal of neurology.

[127]  MTR and T1 provide complementary information in MS NAWM, but not in lesions , 2000, Multiple sclerosis.

[128]  K. Uğurbil,et al.  Magnetic field and tissue dependencies of human brain longitudinal 1H2O relaxation in vivo , 2007, Magnetic resonance in medicine.

[129]  Ralf Deichmann,et al.  Within‐lesion differences in quantitative MRI parameters predict contrast enhancement in multiple sclerosis , 2013, Journal of magnetic resonance imaging : JMRI.

[130]  P. Lundberg,et al.  Novel method for rapid, simultaneous T1, T*2, and proton density quantification , 2007, Magnetic resonance in medicine.

[131]  L. Chang,et al.  Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex , 1999, Neurology.

[132]  P. Renshaw,et al.  Water and metabolite transverse T2 relaxation time abnormalities in the white matter in schizophrenia , 2012, Schizophrenia Research.

[133]  Yonina C. Eldar,et al.  Low‐rank magnetic resonance fingerprinting , 2017, Medical physics.

[134]  L. Shutter,et al.  Proton MRS in acute traumatic brain injury: role for glutamate/glutamine and choline for outcome prediction. , 2004, Journal of neurotrauma.

[135]  H. Larsson,et al.  The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. , 1993, Magnetic resonance imaging.

[136]  Thomas Becker,et al.  MRI T2 relaxation times of brain regions in schizophrenic patients and control subjects , 1997, Psychiatry Research: Neuroimaging.

[137]  Shizhe Li,et al.  Simultaneous determination of metabolite concentrations, T1 and T2 relaxation times , 2017, Magnetic resonance in medicine.

[138]  Klaas Nicolay,et al.  1H MR spectroscopy of the brain: absolute quantification of metabolites. , 2006, Radiology.

[139]  H Merskey,et al.  Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. , 1992, The American journal of psychiatry.

[140]  Ying Lu,et al.  Comparison of T1 and T2 metabolite relaxation times in glioma and normal brain at 3T , 2008, Journal of magnetic resonance imaging : JMRI.

[141]  K. Aydin,et al.  Quantitative Proton MR Spectroscopy Findings in the Corpus Callosum of Patients with Schizophrenia Suggest Callosal Disconnection , 2007, American Journal of Neuroradiology.

[142]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[143]  F. Barkhof,et al.  High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis , 2016, Multiple sclerosis.

[144]  Frederik Barkhof,et al.  MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis , 2006, Magnetic resonance in medicine.

[145]  Kay Nehrke,et al.  T1 corrected B1 mapping using multi‐TR gradient echo sequences , 2010, Magnetic resonance in medicine.